北京若生智能科技有限公司
Drug Database
YE

yellow fever vaccine (Arilvax)

✓ Approved

Novartis AG · 疫苗 · 疫苗

什么是 yellow fever vaccine？

yellow fever vaccine 是一种疫苗，由Novartis AG研发。该药已获批，用于治疗相关适应症，给药途径：Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Arilvax
公司Novartis AG
药物类别疫苗, 大分子
给药途径Injectable (Others), Subcutaneous Injection
状态Approved
来源： ClinicalTrials.gov, Novartis AG

治疗适应症

yellow fever vaccine 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Infections and infestationsYellow fever✓ Approved

相关研究文献

PubMedExpert review of vaccines2026-09-10

Evolution of the global emergency vaccine stockpile system.

Walldorf Jenny A JA, Patel Jaymin C JC, Cibrelus Laurence L, Fernandez Katya K et al.

The emergence of epidemic-prone diseases continues to pose a threat to global health. Vaccine stockpiles allow effective and timely response to outbreaks. Global stockpiles have been established for multiple vaccines, but stockpile management has evolved in recent years, both in the number of globally managed stockpiles and in stockpile strategy, from a reactive to a more integrated approach bridging with preventive strategies. We conducted a review of published and gray literature to provide an update on the evolution of stockpile management in recent years (2014-2025), specifically for cholera, yellow fever, polio, meningococcus, COVID-19, Ebola, and mpox. The benefit of accelerated development of new vaccines and medical countermeasures to fight epidemic-prone diseases cannot be achieved without efficient and transparent stockpile management and distribution mechanisms, to ensure equitable and needs-based allocation.

PMID 42717903
阅读全文 →
PubMedCureus2026-09-10

Recurrent Mumps in a Fully Vaccinated Young Adult With a Prior Breakthrough Infection: A Case Report.

Ramadugu Rithika R, Pidikiti Chandra Varshini CV, Cordero Peña Alesha A, Almonte Angelis A et al.

Mumps is a vaccine-preventable viral disease that typically presents with parotid gland swelling and constitutional symptoms. Although widespread immunization has substantially reduced disease incidence, outbreaks continue to occur among vaccinated populations, raising concerns regarding waning immunity and vaccine failure. Recurrent mumps following both prior natural infection and complete vaccination is uncommon and remains infrequently reported. We describe a 21-year-old woman who presented with a four-day history of fever, malaise, myalgia, and progressive painful swelling of the left parotid gland associated with difficulty chewing and speaking. She had received two doses of measles-mumps-rubella (MMR) vaccine according to the national immunization schedule and had a documented history of mumps infection at nine years of age, occurring after she had already completed her two-dose MMR series (vaccine-breakthrough infection). Physical examination revealed tender unilateral parotid enlargement, cervical lymphadenopathy, and evidence of undernutrition with a body mass index of 16.7 kg/m². Laboratory evaluation demonstrated iron deficiency anemia. Further evaluation, including positive mumps RT-PCR and positive anti-mumps IgM serology, confirmed acute mumps infection, while investigations excluded alternative causes of parotid enlargement. The patient was managed conservatively with isolation, supportive care, nutritional supplementation, and symptomatic treatment, resulting in complete clinical recovery without complications. This case highlights that recurrent mumps can occur despite prior natural infection and complete MMR vaccination. Although waning immunity and host factors such as undernutrition may have contributed to susceptibility, a causal relationship cannot be established from a single case. Continued surveillance and awareness of breakthrough infections remain important, particularly in resource-limited settings.

PMID 42719503
阅读全文 →
PubMedFrontiers in immunology2026-09-10

A bivalent oral yeast vaccine displaying Nocardia seriolae FHA and LMBV MCP confers protection in largemouth bass (Micropterus salmoides).

Lu Jianfei J, Gu Boge B, Yu Pengzhen P, Chen Jiong J

Largemouth bass ranavirus (LMBV) and Nocardia seriolae are major pathogens affecting largemouth bass (Micropterus salmoides), causing significant economic losses. In this study, recombinant yeasts expressing the fibronectin-binding protein A (FHA) of N. seriolae or the major capsid protein (MCP) of LMBV were constructed using the yeast surface display (YSD) system. Based on these recombinant strains, a bivalent oral yeast-based vaccine was developed and its protective efficacy was systematically evaluated. Oral administration of the vaccine induced specific antibodies against FHA and MCP in serum, as well as increased the transcription levels of adaptive immune genes (IgM, IgT, MHC-II) and innate immune genes (IL-1β, TNF-α, IFN-1, Mx2) in the hindgut, liver, and spleen. Importantly, the bivalent oral vaccine provided significant protection against both pathogens in largemouth bass, with relative percent survival (RPS) values of 56.7% against N. seriolae and 63.3% against LMBV. Meanwhile, the oral vaccine reduced pathogen loads and alleviated histopathological lesions. In summary, these findings suggest that the bivalent oral vaccine developed in this study could serve as a promising strategy for controlling N. seriolae and LMBV infections in largemouth bass aquaculture.

PMID 42718698
阅读全文 →
PubMedJournal of medical virology2026-09-10

Admission-Time Clinicolaboratory Phenotypes for Early Differentiation of Severe Fever With Thrombocytopenia Syndrome and Hemorrhagic Fever With Renal Syndrome.

Ma Ruize R, Xu Yanli Y, Ding Shuwen S, Zhang Ruihua R et al.

Early differentiation of severe fever with thrombocytopenia syndrome (SFTS) and hemorrhagic fever with renal syndrome (HFRS) remains difficult in endemic settings. In this single-center retrospective comparative study, we analyzed admission-time demographic, clinical, and laboratory data from 330 hospitalized patients with laboratory-confirmed SFTS (n = 220) or HFRS (n = 110) admitted between May 2023 and November 2025. Compared with HFRS, SFTS showed an older age distribution, female predominance, more frequent neurological symptoms, and a predominantly hematologic phenotype with modest hepatic differences, whereas HFRS showed more prominent urinary manifestations and greater inflammatory and renal abnormalities. Abnormality-based and normalized organ-domain burden analyses supported the same phenotypic separation, with hematologic, renal, and inflammatory domains showing the clearest exploratory differences. Two differentiation models were developed as proof-of-concept tools using the same complete-case data set and internally evaluated by full-process nested cross-validation. The basic and extended models achieved out-of-fold AUCs of 0.975 and 0.971, respectively; the paired difference was -0.004 (95% CI, -0.014 to 0.005; p = 0.404). Adding CRP, albumin, and LDH did not provide consistent incremental predictive value. These single-center findings provide a proof-of-concept framework requiring independent external validation and recalibration before potential clinical application.

PMID 42720266
阅读全文 →
PubMedJournal of general and family medicine2026-09-10

Functional Hyperthermia Presenting as Fever of Unknown Origin With Normal Inflammatory Markers in an Adolescent.

Sada Ryuichi Minoda RM, Miyake Hirofumi H, Akebo Hiroyuki H, Hatta Kazuhiro K

PMID 42719095
阅读全文 →
PubMedMicrobiology resource announcements2026-09-10

Genomic characterization of the attenuated human cytomegalovirus strain TR-VAC developed for subviral particle vaccine production.

Schmidt Hanno H, Hewel Charlotte C, Büscher Nicole N, Linke Matthias M et al.

We report the complete genome sequence of the attenuated human cytomegalovirus strain TR-VAC, developed for subviral particle vaccine production. Oxford Nanopore duplex sequencing confirmed all engineered modifications, including UL130 repair, UL25 stop codons, ddFKBP insertion, GFP deletion, and retention of the bacterial artificial chromosome backbone, without large-scale structural rearrangements.

PMID 42720293
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多yellow fever vaccine